企業を読み込み中
Just reported
Q1 FY2027 results
From Phibro Animal Health's results release of 2026年11月4日; its quarterly report has since been filed.
Revenue
Actual
$386.8M
+6.3% y/y
-2.5% q/qGuided
—
No guide given
EPS, GAAP
Actual
$0.72
+11% y/y
+36% q/qGuided
—
No guide given
EPS, adjusted: $0.79
Operating income, GAAP
Actual
$49.6M
-3.2% y/y
+3.1% q/qGuided
—
No guide given
Company outlook
Q1 FY2027
- Revenue$386.8M+6.3% y/y First given
- EPS, adjusted$0.79First given
- EPS$0.72First given
Full year 2027
- Revenue$1.55B – $1.6B+3.7% y/y Unchanged
- EPS, adjusted$3.41 – $3.59Unchanged
- EPS$2.98 – $3.22Unchanged
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Phibro Animal Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$34.4BA
NBIXNeurocrine Biosciences, Inc.$16.9BA+
ELANElanco Animal Health Incorporated$13.4BA
KNSAKiniksa Pharmaceuticals International, plc$8.2BA+
LQDALiquidia Corporation$5.2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
Phibro Animal Health Corporation 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
